Latest Morning Briefing Stories
The Pill Club Reaches $18.3 Million Medicaid Fraud Settlement With California
The online women’s pharmacy agreed to pay $15 million to the state Department of Justice and $3.3 million to the Department of Insurance over claims it overbilled Medi-Cal.
Decisions by CVS and Optum Panicked Thousands of Their Sickest Patients
Pharmacy closures by two of the biggest home infusion companies point to grave shortages and dangers for patients who require IV nutrition to survive.
Por un tecnicismo, niños necesitados podrían no tener acceso a vacunas contra el VRS
El virus respiratorio sincitial afecta a bebés de todas las clases sociales, pero tiende a perjudicar más a los hogares pobres y hacinados
A Technicality Could Keep RSV Shots From Kids in Need
The Vaccines for Children program, which buys more than half the pediatric vaccines in the U.S., may not cover the RSV shot for babies because it’s not technically a vaccine.
Some Addiction Treatment Centers Turn Big Profits by Scaling Back Care
Private equity groups are cashing in on rising rates of alcohol and drug addiction in the U.S. But they aren’t necessarily investing in centers with the best treatment standards, and they often cut extra services.
KFF Health News' 'What the Health?': Part II: The State of the Abortion Debate 50 Years After ‘Roe’
In Part II of this special two-part episode, Alice Miranda Ollstein of Politico, Sandhya Raman of CQ Roll Call, and Sarah Varney of KHN join KHN chief Washington correspondent Julie Rovner to discuss how the abortion debate has evolved since the Supreme Court overturned the nationwide right to abortion in 2022, and what might be the flashpoints for 2023. Also, for extra credit, the panelists recommend their most memorable reproductive health stories from the last year.
Montana Pharmacists May Get More Power to Prescribe
Supporters of a proposed law say it would fill a health provider gap in rural areas, while doctors worry it will give pharmacists power outside the scope of their education.
FDA Experts Are Still Puzzled Over Who Should Get Which Covid Shots and When
A single booster seems to prevent death and hospitalization in most people, but protection from the current vaccines wanes within months. FDA experts say they need to know more from the Centers for Disease Control and Prevention to decide the best long-term strategy.
KFF Health News' 'What the Health?': Part I: The State of the Abortion Debate 50 Years After ‘Roe’
In Part I of this special two-part episode, Alice Miranda Ollstein of Politico, Sandhya Raman of CQ Roll Call, and Sarah Varney of KHN join KHN chief Washington correspondent Julie Rovner to discuss how the abortion debate has evolved since the Supreme Court overturned the nationwide right to abortion in 2022, and what might be the flashpoints for 2023. Also in this episode, Rovner interviews Elizabeth Nash of the Guttmacher Institute, about changing reproductive policies in the states.
Lo que necesitan saber los adultos mayores sobre covid y Paxlovid
Expertos dicen que la terapia de primera elección debe ser Paxlovid, un tratamiento antiviral para personas con covid leve a moderado con alto riesgo de enfermarse gravemente.
What Older Americans Need to Know About Taking Paxlovid
Covid-19 continues to hit seniors with disproportionate severity. Experts say Paxlovid is an effective therapy that is being underprescribed for people 65 and older.
The Biggest, Buzziest Conference for Health Care Investors Convenes Amid Fears the Bubble Will Burst
This year’s JPMorgan confab, the first since covid’s chilling effect on such gatherings, was full of energy and enthusiasm. But it was also marked by questions about the future of health care investment.
California Attorney General Sues Drugmakers Over Inflated Insulin Prices
California Attorney General Rob Bonta is taking three major drugmakers and three distributors to court, alleging the companies illegally raised prices at the expense of diabetes patients.
KFF Health News' 'What the Health?': GOP House Opens With Abortion Agenda
Leaders of the new Republican-led U.S. House kicked off their legislative agenda with two bills supported by anti-abortion groups. While neither is likely to become law, the move demonstrates how abortion will continue to be an issue in Washington. Meanwhile, as open enrollment for the Affordable Care Act nears its end in most states, the number of Americans covered by the plans hits a new high. Margot Sanger-Katz of The New York Times, Alice Miranda Ollstein of Politico, and Sarah Karlin-Smith of the Pink Sheet join KHN’s Julie Rovner to discuss these topics and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
Fiscal general de California demanda a farmacéuticas por “inflar” los precios de la insulina
En la demanda, Rob Bonta argumentó que los precios se han disparado y que algunos pacientes se han visto obligados a racionar sus medicamentos o renunciar por completo a comprar insulina.
Behavioral Telehealth Loses Momentum Without a Regulatory Boost
As flexible treatment options spurred by the covid pandemic wane, patients relying on medications classified as controlled substances worry that without action to extend the loosened rules, it’ll be harder to get their meds.
NY requiere que doctores receten naloxona a algunos pacientes que toman analgésicos opioides
Aunque los titulares son por las muertes por sobredosis de drogas ilícitas vendidas en la calle, el riesgo de sufrirlas también es real para los pacientes que toman opioides recetados por sus médicos.
NY Docs Are Now Required to Prescribe Naloxone to Some Patients on Opioid Painkillers
This strategy — now in place in at least 10 states — is part of an effort to curb accidental opioid overdose deaths by patients who take these powerful medications.
Readers and Tweeters Chime In on Disability Rights and Drug Discounts
KHN gives readers a chance to comment on a recent batch of stories.
Is Legislation to Safeguard Americans Against Superbugs a Boondoggle or Breakthrough?
While supporters cheer the PASTEUR Act as an essential strategy to stem the rise of antibiotic-resistant pathogens, critics call it a multibillion-dollar giveaway to Big Pharma.
